Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

CPRX 11.19.2024

Full Press ReleaseSEC FilingsOur CPRX Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
  • 01.16.2025 - 43rd Annual J.P. Morgan Healthcare Conference Presentation Details
  • 01.08.2025 - Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Recent Filings

  • 01.21.2025 - EX-99.1 EX-99.1
  • 01.21.2025 - 8-K Current report
  • 01.10.2025 - 4 Statement of changes in beneficial ownership of securities

CORAL GABLES, Fla.,Nov. 19, 2024(GLOBE NEWSWIRE) --Catalyst Pharmaceuticals, Inc.("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced thatRichard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming investor conferences detailed below.

Piper Sandler 36th Annual Healthcare ConferenceDate:Tuesday, December 3, 2024Presentation:2:00 PM ETWebcast Link

Citi's 2024 Global Healthcare ConferenceDate:Wednesday, December 4, 2024Presentation:1:00 PM ETWebcast Link

The webcasts will be available under the Investors section on the Company's website,www.catalystpharma.com, and a replay will be available for at least 30 days.

About Catalyst PharmaceuticalsCatalyst Pharmaceuticals, Inc.(Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-establishedU.S.presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered inCoral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.

For more information, please visit Catalyst's website atwww.catalystpharma.com.

Forward-Looking StatementsThis press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source:Catalyst Pharmaceuticals, Inc.

Investor ContactMary Coleman, Catalyst Pharmaceuticals, Inc.(305) 420-3200mcoleman@catalystpharma.comMedia ContactDavid Schull, Russo Partners(858) 717-2310david.schull@russopartnersllc.com

Primary Logo

Source: Catalyst Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com